Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
11 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05296798 | A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) | active not recruiting | Phase 3 | 922 | Hoffmann-La RocheINDUSTRY | 29 | Sep 29, 2026 | clinicaltrials |
| NCT05894239 | A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer(INAVO122) | recruiting | Phase 3 | 230 | Hoffmann-La Roche |
| 29 |
| Sep 21, 2026 |
| clinicaltrials |
| NCT04543617 | A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy(SKYSCRAPER-07) | completed | Phase 3 | 760 | Hoffmann-La RocheINDUSTRY | 28 | Sep 14, 2026 | clinicaltrials |
| NCT06065748 | A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | active not recruiting | Phase 3 | 1,050 | Hoffmann-La RocheINDUSTRY | 37 | Sep 14, 2026 | clinicaltrials |
| NCT04873362 | A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy(Astefania) | active not recruiting | Phase 3 | 1,188 | Hoffmann-La RocheINDUSTRY | 32 | Sep 3, 2026 | clinicaltrials |
| NCT06281119 | Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years | active not recruiting | Phase 3 | 450 | Serum Institute of India Pvt. Ltd.INDUSTRY | 3 | Jun 29, 2026 | clinicaltrials |
| NCT04961996 | A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | active not recruiting | Phase 3 | 4,170 | Hoffmann-La RocheINDUSTRY | 54 | Jun 17, 2026 | clinicaltrials |
| NCT05415215 | A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer(ProHer) | completed | Phase 3 | 346 | Hoffmann-La RocheINDUSTRY | 17 | Feb 10, 2026 | clinicaltrials |
| NCT03284866 | HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV(COVENANT) | completed | Phase 3 | 536 | AIDS Malignancy ConsortiumNETWORK | 5 | Jan 28, 2026 | clinicaltrials |
| NCT05904886 | A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)(SKYSCRAPER-14) | active not recruiting | Phase 3 | 687 | Hoffmann-La RocheINDUSTRY | 27 | Dec 31, 2025 | clinicaltrials |
| NCT01352117 | Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma(REACT-KS) | completed | Phase 3 | 192 | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsNETWORK | 6 | Nov 14, 2019 | clinicaltrials |
Data updated 3 hours agoSource updated unknownsource: clinicaltrials